MedPacto Announces Two Achievements at the American Association for Cancer Immunotherapy Conference

BaektoSertip Biomarker 'VRGS' Selected for Early Results and Oral Presentation
BaektoSertip-Imfinzi Combination Phase 2a Clinical Trial Interim Results to Be Shared

[Asia Economy Reporter Eunmo Koo] MedPacto announced on the 5th that two presentations on 'Vactosertib' have been confirmed at the Society for Immunotherapy of Cancer (SITC 2020) conference to be held in the United States next month.

MedPacto plans to present preliminary results on the discovery of the VRGS (Vactosertib Response Gene Signature) biomarker in combination clinical trials targeting colorectal cancer patients.

Currently, MedPacto is verifying the VRGS biomarker discovered through genomic analysis of patients in this clinical trial, aiming for personalized treatment based on response rates. The company expects that once this clinical trial is established, the drug can be selectively administered only to patients predicted to have high treatment efficacy, ultimately leading to a breakthrough improvement in treatment outcomes.

Additionally, at this conference, interim results of the phase 1b/2a combination clinical trial of Vactosertib and the immuno-oncology drug 'Imfinzi' in non-small cell lung cancer patients will also be presented.

This clinical trial has completed phase 1b and is currently in phase 2a, administering treatment to patients with PD-L1 expression of 1% or higher, who are considered to have a higher likelihood of response, so meaningful clinical results are expected.

Last year at SITC, MedPacto attempted treatment on patients with PD-L1 expression below 25%, achieving an objective response rate (ORR) of 16.7%. This is significantly higher than the ORR of 2.8% observed with Imfinzi monotherapy.

A MedPacto representative stated, “The preliminary results on biomarker discovery will be presented orally on November 13,” adding, “This presentation will demonstrate the high medical value of Vactosertib and provide insight into the potential success of MedPacto’s ongoing clinical trials.”

This year’s SITC will be held online from the 10th to the 14th of next month.

Vactosertib is a new drug candidate discovered at Ewha Womans University from 2008 to 2013 with support from the Ministry of Education, Science and Technology. MedPacto has previously conducted phase 1 clinical trials jointly with the National Cancer Center-led National Cancer New Drug Development Project (designated by the Ministry of Health and Welfare).

This content was produced with the assistance of AI translation services.